Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Adaptive Biotechnologies and Takeda Oncology.

Medical Crossfire®: Applying the Evidence in Acute Lymphoblastic Leukemia From Pediatric to Adult Case Scenarios

Release Date: December 23, 2021
Expiration Date: December 23, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in acute lymphoblastic leukemia (ALL) care. In this educational program, these experts use a case-based format to review patient scenarios, reflect on how they might handle particular cases, integrate relevant evidence into real-world practice, and compare their patient care approaches with those of experts and peers. Additionally, these experts discuss methods to best integrate the latest therapies into ALL treatment paradigms, address barriers to optimized integration of novel agents, as well as provide best practices for the management of adverse events

This educational activity is an archive of the live virtual symposium held on December 16, 2021.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Adaptive Biotechnologies and Takeda Oncology.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

These activities are intended for physicians interested in the treatment of patients with ALL.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Develop individualized treatment strategies for adults and pediatric patients with ALL based on cytogenetic and immunophenotype characteristics
Apply current and emerging data regarding the role of minimal residual disease assessment in determining prognosis and in treatment planning for adult as well as AYA patients with ALL
Assess the efficacy and safety of current and emerging therapies including monoclonal antibodies, antibody-drug conjugates, and CAR T-cell therapies in the management of patients with ALL
Discuss evidence-based recommendations in the context of the role of antibody therapy in newly diagnosed or relapsed/refractory ALL management, including in Ph-negative or -positive disease, as a pretransplant strategy, or in patients with residual disease

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities

Chair

Elias Jabbour, MD
Professor of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: AbbVie, Adaptive Biotechnologies; Amgen Inc., Bristol Myers Squibb, Pfizer Inc., Spectrum Pharmaceuticals, Inc., Takeda.

Faculty

Monika Brueggemann, PhD (medicine)
Head, Unit for Hematological Diagnostics
University Hospital Schleswig-Holstein
Kiel, Germany

Disclosures: Grant/Research Support: Amgen Inc., Consultant: Amgen Inc., Incyte, Speaker’s Bureau: Amgen Inc., BD, Molecular Health, Janssen, Celgene Corporation, Novartis.

Stephan A. Grupp, MD, PhD
Novotny Professor of Pediatrics
Perelman School of Medicine
University of Pennsylvania
Chief, Cellular Therapy and Transplantation Section
Medical Director, Cell and Gene Therapy Laboratory
Children’s Hospital of Philadelphia
Philadelphia, PA

Disclosures: Grant/Research Support: Novartis, Kite Pharma, Vertex Pharmaceuticals, Servier Pharmaceuticals, Consultant: Novartis, F. Hoffmann-La Roche Ltd, GlaxoSmithKline, Humanigen, Inc., Cellular Biomedicine Group, Inc., Eureka Therapeutics, Janssen/Johnson & Johnson, Other Support: SAB or SCC member for Novartis, Jazz Pharmaceuticals, Adaptimmune Therapeutics plc, TCR2 Therapeutics, Cellectis, Juno Therapeutics, Vertex Pharmaceuticals, Allogene Therapeutics, Cabaletta Bio.

Hagop Kantarjian, MD
Professor and Chair, Department of Leukemia
University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: AbbVie Inc., Amgen Inc., Ascentage Pharma, Bristol Myers Squibb, Daiichi Sankyo, ImmunoGen, Inc., Jazz Pharmaceuticals, Novartis, Pfizer Inc., Consultant: AbbVie Inc., Amgen Inc., Aptitude Health, Ascentage Pharma, Astellas Pharma, AstraZeneca, Ipsen Biopharmaceuticals, KAHR Medical Ltd, NOVA Research Company, Novartis, Pfizer Inc., Precision BioSciences, Taiho Pharma Canada.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.